PMC:7571312 / 20372-20592
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T16632 | 85-92 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T335 | 85-92 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T336 | 130-134 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T129 | 0-220 | Sentence | denotes | Although irreversible inhibition can provide an extended pharmacodynamic effect when protein resynthesis rate is slow compared to drug clearance, such extended effects for 3CLpro inhibition were not necessarily expected. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 537 | 172-178 | Chemical | denotes | 3CLpro |